Share Twitter LinkedIn Facebook Email Kathryn Kolibaba, MD of US Oncology Research gives an overview of the results from the BRIGHT study and its impact on treatment for indolent non-hodgkin lymphoma patients. This was recorded at the 2017 Annual Meeting Annual Meeting in Chicago, IL.
FDA grants accelerated approval to ponatinib (ICLUSIG®) with chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia Acute Lymphoblastic Leukemia 3 Mins Read
FDA Approves Inotuzumab Ozogamicin (BESPONSA) for Acute Lymphoblastic Leukemia in Pediatric Patients [Exclusive Video] Acute Lymphoblastic Leukemia 3 Mins Read
Spotlight on CAR T-cell Therapy in 2024: Advances & Clinical Insights Acute Lymphoblastic Leukemia 3 Mins Read